Kinaxo contributes its quantitative phosphoproteomics platform to a drug efficiency study

(PresseBox) ( Martinsried, )
Kinaxo Biotechnologies GmbH announced today that it was awarded a grant by the Bavarian Research Foundation (Bayerische Forschungsstiftung) to expand applications for its quantitative phosphoproteomics platform to contribute to a drug efficacy study.

Quantitative phoshpoproteomics enables analysis of the phosphoproteome, which includes all phosphorylation events occurring in a specific cell line or tissue. Since the majority of targeted small molecules used as anticancer drugs influence the cell's signal transduction pathways, quantification of phosphorylation patterns in relation to drug administration delivers insights into a compound's cellular mode of action. Moreover, non-responsiveness to a multitude of compounds is a fundamental problem in cancer treatment. Here, quantitative phosphoproteomics is a powerful method to unveil the mechanisms of both cellular resistance and a drug's effect. Furthermore, it can be a valuable tool to discover predictive biomarkers that foretell the therapeutic outcome in a patient which in turn allows a targeted therapy approach.

To develop new methods for individualized tumor therapy in pancreatic cancer, Kinaxo Biotechnologies GmbH has now joined an interdisciplinary collaboration with Priaxon AG, Genomatix Software GmbH, the Technical University Munich and the University Hospital "Rechts der Isar" to perform a large-scale drug efficiency study.

Despite the fact that several small molecules show significant promise for the treatment of pancreatic cancer, so far no considerable breakthroughs have been achieved. The disease shows a mortality rate of 95%, with crucial tumor-relevant processes being very poorly understood and only a vanishing number of patients responding to standard therapies. Therefore, the aim of the collaboration is to establish tools for identifying tumor-relevant signal transduction pathways and therapeutic targets. Kinaxo will use its quantitative phosphoproteomics approach to evaluate the efficacy of established and new compounds for pancreatic cancer treatment and to try to identify predictive biomarkers that facilitate the design and monitoring of individualized therapeutic strategies.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an